Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation.
Research Сenter for Molecular Mechanisms of Aging and Age-related Diseases, Moscow Institute of Physics and Technology, Dolgoprudniy, Russian Federation.
Biophys Chem. 2024 Oct;313:107290. doi: 10.1016/j.bpc.2024.107290. Epub 2024 Jul 10.
Due to their fundamental biological importance, membrane proteins (MPs) are attractive targets for drug discovery, with cell surface receptors, transporters, ion channels, and membrane-bound enzymes being of particular interest. However, due to numerous challenges, these proteins present underutilized opportunities for discovering biotherapeutics. Antibodies hold the promise of exquisite specificity and adaptability, making them the ideal candidates for targeting complex membrane proteins. They can target specific conformations of a particular membrane protein and can be engineered into various formats. Generating specific and effective antibodies targeting these proteins is no easy task due to several factors. The antigen's design, antibody-generation strategies, lead optimization technologies, and antibody modalities can be modified to tackle these challenges. The rational employment of cutting-edge lipid nanoparticle systems for retrieving the membrane antigen has been successfully implemented to simplify the mechanism-based therapeutic antibody discovery approach. Despite the highlighted MP production challenges, this review unequivocally underscores the advantages of targeting complex membrane proteins with antibodies and designing membrane protein antigens. Selected examples of lipid nanoparticle success have been illustrated, emphasizing the potential of therapeutic antibody discovery in this regard. With further research and development, we can overcome these challenges and unlock the full potential of therapeutic antibodies directed to target complex MPs.
由于其在生物学上的重要性,膜蛋白(MPs)是药物发现的有吸引力的靶点,细胞表面受体、转运蛋白、离子通道和膜结合酶尤其受到关注。然而,由于存在许多挑战,这些蛋白质在发现生物治疗药物方面的机会尚未得到充分利用。抗体具有极高的特异性和适应性的潜力,是靶向复杂膜蛋白的理想候选物。它们可以针对特定膜蛋白的特定构象,并可以设计成各种形式。由于多种因素,生成针对这些蛋白质的特异性和有效的抗体并非易事。可以修改抗原设计、抗体生成策略、先导优化技术和抗体模式,以应对这些挑战。合理利用先进的脂质纳米颗粒系统来回收膜抗原,已成功地简化了基于机制的治疗性抗体发现方法。尽管突出了 MP 生产方面的挑战,但本综述明确强调了使用抗体靶向复杂膜蛋白和设计膜蛋白抗原的优势。本文还举例说明了脂质纳米颗粒的成功案例,强调了在这方面发现治疗性抗体的潜力。随着进一步的研究和开发,我们可以克服这些挑战,充分发挥针对复杂 MPs 的治疗性抗体的潜力。